Literature DB >> 17596427

Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination.

Fengling Luo1, Yong Feng, Min Liu, Pingfei Li, Qin Pan, Victor Tunje Jeza, Bing Xia, Jianguo Wu, Xiao-Lian Zhang.   

Abstract

Attenuated Salmonella enterica serovar Typhi strains have been considered to be attractive as potential live oral delivery vector vaccines because of their ability to elicit the full array of immune responses in humans. In this study, we constructed an attenuated S. enterica serovar Typhi strain stably expressing conserved nucleocapsid (N) protein of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) by integrating the N gene into the pilV gene, which was under the control of the type IVB pilus operon promoter in S. enterica serovar Typhi. BALB/c mice were immunized with this recombinant strain through different routes: intranasally, orogastrically, intraperitoneally, and intravenously. Results showed that the intranasal route caused the highest production of specific immunoglobulin G (IgG), IgG2a, and secretory IgA, where IgG2a was imprinted as a Th1 cell bias. Moreover, this recombinant live vaccine induced significantly high levels of specific cytotoxic T-lymphocyte activities and increased gamma interferon-producing T cells compared with the parental strain. Our work provides insights into how the type IVB pilus operon promoter controlling SARS-CoV N gene expression in Salmonella might be attractive for a live-vector vaccine against SRAS-CoV infection, for it could induce mucosal, humoral, and cellular immune responses. Our work also indicates that the type IVB pilus operon promoter controlling foreign gene expression in Salmonella can elicit full immune responses by intranasal vaccination.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17596427      PMCID: PMC2044483          DOI: 10.1128/CVI.00076-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  42 in total

Review 1.  Elicitation of predictable immune responses by using live bacterial vectors.

Authors:  B Drabner; C A Guzmán
Journal:  Biomol Eng       Date:  2001-03

Review 2.  Bacterial systems for the delivery of eukaryotic antigen expression vectors.

Authors:  G Dietrich; S Spreng; I Gentschev; W Goebel
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2000-10

Review 3.  Exploiting the immune system: toward new vaccines against intracellular bacteria.

Authors:  J Hess; U Schaible; B Raupach; S H Kaufmann
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

4.  Surface-displayed viral antigens on Salmonella carrier vaccine.

Authors:  J S Lee; K S Shin; J G Pan; C J Kim
Journal:  Nat Biotechnol       Date:  2000-06       Impact factor: 54.908

5.  Salmonella enterica serovar typhi uses type IVB pili to enter human intestinal epithelial cells.

Authors:  X L Zhang; I S Tsui; C M Yip; A W Fung; D K Wong; X Dai; Y Yang; J Hackett; C Morris
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

6.  Anti-tumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding beta-galactosidase fused to an envelope protein of endogenous retrovirus.

Authors:  J Takeda; Y Sato; H Kiyosawa; T Mori; S Yokoya; A Irisawa; M Miyata; K Obara; T Fujita; T Suzuki; R Kasukawa; A Wanaka
Journal:  Cell Immunol       Date:  2000-08-25       Impact factor: 4.868

7.  In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors.

Authors:  T E Pickett; M F Pasetti; J E Galen; M B Sztein; M M Levine
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

8.  A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model.

Authors:  M F Pasetti; T E Pickett; M M Levine; M B Sztein
Journal:  Vaccine       Date:  2000-08-01       Impact factor: 3.641

9.  Nasal vaccination with attenuated Salmonella typhimurium strains expressing the Hepatitis B nucleocapsid: dose response analysis.

Authors:  D Nardelli-Haefliger; J Benyacoub; R Lemoine; S Hopkins-Donaldson; A Potts; F Hartman; J P Kraehenbuhl; P De Grandi
Journal:  Vaccine       Date:  2001-04-06       Impact factor: 3.641

10.  Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients.

Authors:  Hui Peng; Li-tao Yang; Ling-yun Wang; Jian Li; Jun Huang; Zhi-qiang Lu; Richard A Koup; Robert T Bailer; Chang-you Wu
Journal:  Virology       Date:  2006-05-11       Impact factor: 3.616

View more
  7 in total

1.  Comparative immunological evaluation of recombinant Salmonella Typhimurium strains expressing model antigens as live oral vaccines.

Authors:  Song-yue Zheng; Bin Yu; Ke Zhang; Min Chen; Yan-Hong Hua; Shuofeng Yuan; Rory M Watt; Bo-Jian Zheng; Kwok-Yung Yuen; Jian-Dong Huang
Journal:  BMC Immunol       Date:  2012-09-26       Impact factor: 3.615

Review 2.  Betacoronavirus Genomes: How Genomic Information has been Used to Deal with Past Outbreaks and the COVID-19 Pandemic.

Authors:  Alejandro Llanes; Carlos M Restrepo; Zuleima Caballero; Sreekumari Rajeev; Melissa A Kennedy; Ricardo Lleonart
Journal:  Int J Mol Sci       Date:  2020-06-26       Impact factor: 5.923

Review 3.  Severe acute respiratory syndrome (SARS).

Authors:  Dennis J Cleri; Anthony J Ricketti; John R Vernaleo
Journal:  Infect Dis Clin North Am       Date:  2010-03       Impact factor: 5.982

Review 4.  Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence.

Authors:  Daniele Focosi; Fabrizio Maggi; Arturo Casadevall
Journal:  Viruses       Date:  2022-01-19       Impact factor: 5.048

5.  A novel recombinant bacterial vaccine strain expressing dual viral antigens induces multiple immune responses to the Gag and gp120 proteins of HIV-1 in immunized mice.

Authors:  Yong Feng; Shiqun Wang; Fenglin Luo; Ying Ruan; Lei Kang; Xiaohui Xiang; Tao Chao; Guiqing Peng; Chengliang Zhu; Yongxin Mu; Ying Zhu; Xiaolian Zhang; Jianguo Wu
Journal:  Antiviral Res       Date:  2008-07-17       Impact factor: 5.970

Review 6.  SARS vaccines: where are we?

Authors:  Rachel L Roper; Kristina E Rehm
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

Review 7.  Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Pediatr Infect Dis J       Date:  2020-05       Impact factor: 3.806

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.